LGND - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Ligand Corp

Ligand Pharmaceuticals (LGND) bases its strategy on the aggressive acquisition of intellectual property and third-party startups. This "royalty farm" model enables the company to monetize B2B partnerships with R&D behemoths. A flawless reputation in solubility technologies is confirmed by the annual sales volume growth chart for the TTM, where the value of 1.00 aligns with the current metric, demonstrating the resilience of fundamental sales.
Ligand Pharma (LGND) - פילוחי מדדים ודוחות פיננסיים

Analyzing business expansion rates is critical for identifying the fundamental drivers of stability for Ligand Pharmaceuticals (LGND). This TTM revenue growth rate relative to the previous year is calculated as the percentage change in total income over a rolling year, allowing systemic trends to be isolated from short-term noise. For a company that accumulates royalties without incurring production costs, this indicator directly reflects the commercial success of partner drugs.